CR20150592A - Composiciones y métodos para alterar la señalización del segundo mensajero - Google Patents

Composiciones y métodos para alterar la señalización del segundo mensajero

Info

Publication number
CR20150592A
CR20150592A CR20150592A CR20150592A CR20150592A CR 20150592 A CR20150592 A CR 20150592A CR 20150592 A CR20150592 A CR 20150592A CR 20150592 A CR20150592 A CR 20150592A CR 20150592 A CR20150592 A CR 20150592A
Authority
CR
Costa Rica
Prior art keywords
compositions
methods
messenger
alter
signaling
Prior art date
Application number
CR20150592A
Other languages
English (en)
Inventor
Dinshaw J Patel
Thomas Tuschl
Manuel Ascano
Yang Wu
Yizhou Liu
Winfried Barchet
Gunther Hartmann
Thomas Zillinger
Roger Jones
Barbara L Gaffney
Pu Gao
Original Assignee
Sloan Kettering Inst Cancer
Univ Rockefeller
Univ Rutgers
Univ Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Univ Rockefeller, Univ Rutgers, Univ Bonn filed Critical Sloan Kettering Inst Cancer
Publication of CR20150592A publication Critical patent/CR20150592A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/698—Matching; Classification
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)

Abstract

La invención se refiere a composiciones, métodos, kits y ensayos en relación con el uso y/o explotación de isómeros de cGAMP así como la estructura de la enzima cGAS.
CR20150592A 2013-04-29 2015-10-29 Composiciones y métodos para alterar la señalización del segundo mensajero CR20150592A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361817269P 2013-04-29 2013-04-29
US201361819369P 2013-05-03 2013-05-03
PCT/US2014/035909 WO2014179335A1 (en) 2013-04-29 2014-04-29 Compositions and methods for altering second messenger signaling

Publications (1)

Publication Number Publication Date
CR20150592A true CR20150592A (es) 2016-04-04

Family

ID=51843894

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150592A CR20150592A (es) 2013-04-29 2015-10-29 Composiciones y métodos para alterar la señalización del segundo mensajero

Country Status (27)

Country Link
US (4) US9840533B2 (es)
EP (2) EP4398254A3 (es)
JP (2) JP2016524593A (es)
KR (1) KR20160024850A (es)
CN (2) CN105358158A (es)
AP (1) AP2015008746A0 (es)
AU (1) AU2014260015B2 (es)
BR (1) BR112015027327B1 (es)
CA (2) CA2908154C (es)
CL (1) CL2015003088A1 (es)
CR (1) CR20150592A (es)
CU (1) CU24376B1 (es)
DO (1) DOP2015000269A (es)
EA (1) EA201592074A1 (es)
EC (1) ECSP15049909A (es)
ES (1) ES2982836T3 (es)
GT (1) GT201500317A (es)
HK (1) HK1221414A1 (es)
IL (1) IL241567B (es)
MX (1) MX374828B (es)
NI (1) NI201500156A (es)
PE (1) PE20160167A1 (es)
PH (1) PH12015502388A1 (es)
SA (1) SA515370079B1 (es)
SG (2) SG11201508165VA (es)
TN (1) TN2015000457A1 (es)
WO (1) WO2014179335A1 (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
PL2931738T3 (pl) 2012-12-13 2019-07-31 Aduro Biotech, Inc. Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
PT2934598T (pt) * 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
WO2014179335A1 (en) * 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
RS59500B1 (sr) * 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
EP3027227A4 (en) * 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
PE20170198A1 (es) 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
CA2961894C (en) * 2014-09-19 2023-12-12 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastatis using gap junction inhibitors
EP3546473B1 (en) * 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2016100261A2 (en) * 2014-12-17 2016-06-23 Lipogen Llc Method of treating cancer with cgamp or cgasmp
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1248603A1 (zh) * 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CR20180101A (es) 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
CA3002236A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
WO2017123657A1 (en) * 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
RS67188B1 (sr) * 2016-01-11 2025-10-31 Innate Tumor Immunity Inc Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
DK3439667T3 (da) 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US20190161754A1 (en) * 2016-06-13 2019-05-30 The Regents Of The University Of California Fluorescent biosensor for 2', 3'-cgamp
WO2018009466A1 (en) * 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
US20190345191A1 (en) * 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
EP3523314A1 (de) * 2016-10-07 2019-08-14 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US11492367B2 (en) 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
CA3053568A1 (en) 2017-02-21 2018-08-30 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
ES2904317T3 (es) * 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
US11667663B2 (en) * 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US10947263B2 (en) * 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
EA038805B1 (ru) * 2017-11-21 2021-10-21 Такеда Фармасьютикал Компани Лимитед Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
WO2019118839A1 (en) * 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US10966999B2 (en) * 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) * 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
SG11202008636YA (en) 2018-03-23 2020-10-29 Codiak Biosciences Inc Extracellular vesicles comprising sting-agonist
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
TWI833744B (zh) * 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020006038A1 (en) * 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Structure of the human cgas-dna complex and uses thereof
EP3820477A4 (en) 2018-07-10 2022-07-13 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
MX2020013322A (es) * 2018-08-16 2021-02-22 Eisai R&D Man Co Ltd Sales de compuestos y cristales de los mismos.
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
KR102567590B1 (ko) 2018-09-06 2023-08-17 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트
MX2021003295A (es) 2018-09-27 2021-07-16 Pf Medicament Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
AU2019371206A1 (en) 2018-10-29 2021-05-27 Venenum Biodesign, LLC Novel sting agonists
WO2020092633A1 (en) 2018-10-30 2020-05-07 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
WO2020092617A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
WO2020087126A1 (en) * 2018-11-02 2020-05-07 The Walter And Eliza Hall Institute Of Medical Research Methods of treatment, prevention and diagnosis
CN114080232A (zh) 2019-03-21 2022-02-22 科迪亚克生物科学公司 用于疫苗递送的细胞外囊泡
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2020205323A1 (en) * 2019-03-29 2020-10-08 Merck Sharp & Dohme Corp. Stable formulations of cyclic dinucleotide sting agonist compounds and methods of use thereof
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
US20220395465A1 (en) 2019-09-25 2022-12-15 Codiak Biosciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
CA3152478A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Extracellular vesicle compositions
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US20230203532A1 (en) * 2019-11-28 2023-06-29 Mcmaster University Recombinant polypeptides for programming extracellular vesicles
BR112022017136A2 (pt) 2020-02-28 2022-10-11 Tallac Therapeutics Inc Conjugação mediada por transglutaminase
CA3168368A1 (en) 2020-03-06 2021-09-10 Masayuki Ishizaki Antibody-drug conjugate including novel cyclic dinucleotide derivative
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
CN111243668B (zh) * 2020-04-09 2020-08-07 腾讯科技（深圳）有限公司 分子结合位点检测方法、装置、电子设备及存储介质
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
JP2023533111A (ja) 2020-05-15 2023-08-02 イミューンセンサー セラピューティクス、インコーポレイテッド 免疫チェックポイント阻害剤とのｓｔｉｎｇアゴニスト併用治療
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
TW202227479A (zh) 2020-09-02 2022-07-16 日商第一三共股份有限公司 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
CA3191593A1 (en) 2020-09-08 2022-03-17 Jinming Gao Polyvalent sting activating compositions and uses thereof
US20230366794A1 (en) 2020-09-23 2023-11-16 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
TW202241516A (zh) 2020-12-17 2022-11-01 美商杜夫特學院信託管理公司 經fap活化之放射性治療診斷(radiotheranostics)，與其相關用途
US12404261B2 (en) * 2020-12-22 2025-09-02 Novartis Ag Compounds and compositions for treating conditions associated with cGAS
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
CN113265435A (zh) * 2021-06-16 2021-08-17 中国农业科学院兰州兽医研究所 一种细菌第二信使分子环二核苷酸的制备方法
AU2022315305A1 (en) 2021-07-23 2024-02-01 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
CN113569876A (zh) * 2021-08-31 2021-10-29 东软睿驰汽车技术（沈阳）有限公司 图像特征提取方法、装置和电子设备
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
US20250207169A1 (en) 2022-03-02 2025-06-26 Daiichi Sankyo Company, Limited METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
AU2023336004A1 (en) 2022-08-29 2025-03-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy
CN116253766B (zh) * 2023-03-27 2024-08-27 瑞阳（上海）新药研发有限公司 一种环二核苷酸2’,3’-cGAMP的制备方法
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
WO1999038954A1 (en) 1998-02-02 1999-08-05 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
DE60021354T2 (de) 1999-02-15 2006-04-27 Nippon Shinyaku Co., Ltd. Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
JP4638098B2 (ja) 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
JP2004521857A (ja) 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
WO2002059575A2 (en) 2001-01-23 2002-08-01 The Trustees Of Princeton University, Princeton University Method and apparatus for analysis of biological solutions
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004007718A2 (en) 2002-07-10 2004-01-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna-interference by single-stranded rna molecules
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
AU2004275696B2 (en) 2003-07-28 2010-02-18 Karagen Pharmaceuticals, Inc. Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP2007533647A (ja) 2003-10-24 2007-11-22 アルザ・コーポレーシヨン 脂質粒子の調製
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP1729781B1 (en) 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US8088902B2 (en) 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP2399924B1 (en) 2004-05-27 2015-01-28 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid
AU2005328382C1 (en) 2004-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CA2607579A1 (en) 2005-05-06 2006-11-23 The Regents Of The University Of California Microfluidic system for identifying or sizing individual particles passing through a channel
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP1971371B1 (en) 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
WO2007131286A1 (en) 2006-05-16 2007-11-22 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
AU2007292302A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
WO2008052295A1 (en) 2006-10-30 2008-05-08 Universidade Federal De Minas Gerais Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products
WO2008089532A1 (en) 2007-01-26 2008-07-31 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
EP2324044A4 (en) 2008-08-04 2012-04-25 Univ Miami STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
WO2010104883A1 (en) 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
US20110293558A1 (en) 2010-03-22 2011-12-01 Massachusetts Institute Of Technology Material properties of t cells and related methods and compositions
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
BR112012027745A2 (pt) 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia
US8450293B2 (en) * 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
AU2011349278C1 (en) 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
AU2012243396A1 (en) 2011-04-15 2013-10-31 The University Of British Columbia Method and apparatus for separation of particles
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
JP2015516989A (ja) 2012-04-30 2015-06-18 バーバー, グレン, エヌ.BARBER, Glen, N. 免疫反応の変調
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
PL2931738T3 (pl) 2012-12-13 2019-07-31 Aduro Biotech, Inc. Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
PT2934598T (pt) * 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
EP2996472B1 (en) * 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
US10092644B2 (en) 2013-11-22 2018-10-09 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
PE20170198A1 (es) 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
CR20180101A (es) * 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物

Also Published As

Publication number Publication date
EP2991655A1 (en) 2016-03-09
DOP2015000269A (es) 2016-02-29
MX374828B (es) 2025-03-06
PE20160167A1 (es) 2016-04-21
TN2015000457A1 (en) 2017-04-06
US20180118777A1 (en) 2018-05-03
CA2908154A1 (en) 2014-11-06
BR112015027327B1 (pt) 2022-08-02
CU24376B1 (es) 2018-12-05
HK1221652A1 (en) 2017-06-09
US11014956B2 (en) 2021-05-25
EP4398254A3 (en) 2024-10-23
AU2014260015A1 (en) 2015-10-15
US20160068560A1 (en) 2016-03-10
ECSP15049909A (es) 2019-03-29
MX2015014734A (es) 2016-06-28
US20180127454A1 (en) 2018-05-10
BR112015027327A2 (pt) 2017-11-21
US10385091B2 (en) 2019-08-20
CN112386604A (zh) 2021-02-23
CU20150149A7 (es) 2016-07-29
EP2991655B1 (en) 2024-04-10
KR20160024850A (ko) 2016-03-07
GT201500317A (es) 2018-11-27
AP2015008746A0 (en) 2015-09-30
CA2908154C (en) 2023-11-28
ES2982836T3 (es) 2024-10-17
PH12015502388A1 (en) 2016-02-22
US20190330257A1 (en) 2019-10-31
EP2991655A4 (en) 2017-01-04
JP2016524593A (ja) 2016-08-18
EP4398254A2 (en) 2024-07-10
CL2015003088A1 (es) 2016-04-15
HK1221414A1 (zh) 2017-06-02
CA3216501A1 (en) 2014-11-06
JP2019137692A (ja) 2019-08-22
NI201500156A (es) 2015-11-30
SA515370079B1 (ar) 2018-06-28
CN105358158A (zh) 2016-02-24
AU2014260015B2 (en) 2019-11-14
WO2014179335A1 (en) 2014-11-06
NZ712588A (en) 2020-11-27
EA201592074A1 (ru) 2016-02-29
US10131686B2 (en) 2018-11-20
US9840533B2 (en) 2017-12-12
JP6718541B2 (ja) 2020-07-08
SG10201708821RA (en) 2017-12-28
SG11201508165VA (en) 2015-11-27
IL241567B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CR20150592A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
MX2019011764A (es) Composiciones limpiadoras y usos de las mismas.
MX2018002831A (es) Polipeptidos.
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
MX390762B (es) Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas
MX373334B (es) Composiciones y métodos.
CL2024000367A1 (es) Anticuerpos antifactor de la coagulación xi.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
MX373580B (es) Composiciones y métodos de limpieza.
GT201500014S (es) Diseño de botella
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
TWD194157S (zh) 車輛擋風玻璃
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
UA116372C2 (uk) Частинки резинату фенілефрину
MX2018004427A (es) Composicion heterofasica.
ES2571439T3 (es) Cepa de Glomus iranicum var. tenuihypharum var. nov. y su uso como bionematicida
RU2012113484A (ru) Ангоб
ECSDI17009504S (es) Diseño exterior del vehiculo
TWD180149S (zh) 淨水器（二）
TWD180150S (zh) 淨水器（三）
UA85535U (ru) Пролетный пенобетонный элемент с армированием просечно-вытяжной сеткой